Since the late 1990s, tumor necrosis factor alpha (TNF-α) inhibitors (anti-TNFs) have
revolutionized the therapy of immune-mediated inflammatory diseases (IMIDs) affecting the …

Introduction Pustular psoriasis is a group of skin diseases characterized by neutrophil
infiltration in the epidermis and formation of sterile pustules. Conventional treatments, such …

Background Moderate‐to‐severe atopic dermatitis (AD) in the adolescence is a high burden
disease, and its treatment can be very challenging due to paucity of approved systemic …

Psoriasis is a common chronic inflammatory multisystemic disease with a complex
pathogenesis consisting of genetic, immunological, and environmental components. It is …

Abstract Adverse Drug Reactions (ADRs) are common and influence negatively the patient's
therapeutic options. They recognize multiple pathogenic mechanisms, some of …

Due to its anti-hyperglycemic effect, metformin is the first-line medication for the treatment of
type 2 diabetes, particularly in people who are obese. However, metformin is a drug with a …

Introduction Biologics serve as a cornerstone in psoriasis treatment, with low disease activity
or sometimes even clinical remission as a realistic treatment outcome. So far, it is unclear …

Dose reduction (DR) of biologics, where possible, seems promising for more efficient use of
expensive biologics. For implementation of DR strategies, it is essential to get insight in …

Background Dose reduction of biologics for psoriasis is applied in daily practice, although
guidelines are lacking. Striving for clear criteria is important, as it leads to a consistent …

Background/objectives Tightly-controlled dose reduction was possible during 1 year in
psoriasis patients on adalimumab, etanercept or ustekinumab with low disease activity …